Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics Incorporated

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Rhythm Pha...

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Rhythm Pharmaceuticals (RYTM)

In a report released on January 21, Leonid Timashev from RBC Capital maintained a Buy rating on Cytokinetics, with a price target of $95.00. The co...

RBC Capital Reaffirms Their Buy Rating on Cytokinetics (CYTK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Anavex Life Sciences (AVXL – Research Report), Cytok...

Analysts Are Bullish on These Healthcare Stocks: Anavex Life Sciences (AVXL), Cytokinetics (CYTK)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report) and Pfizer (...

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Pfizer (PFE)

In a report released yesterday, Roanna Ruiz from Leerink Partners reiterated a Buy rating on Cytokinetics. The company’s shares closed yesterday at...

Leerink Partners Keeps Their Buy Rating on Cytokinetics (CYTK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN – Research Report), Cytokinetics (CYTK –...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Cytokinetics, with a price target of $65.00....

Current Quarter	$-1.48	Next Quarter	$-1.63
Current Year	$-5.61	Next Year	$-5.99
QoQ Growth	-10.1%	YoY Growth	-6.8%
3Y EPS CAGR	-23.4%	Target Price	$89.37
Consensus	Buy	Upside	+38.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CYTK	$64.70	-0.71%	966.10K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CYTK	$64.70	-0.7%	966.10K
3
4
5
6

CYTK

CYTK

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Cytokinetics Incorporated Data in Excel

Get Cytokinetics Incorporated Data in Excel